FDA approves Leo Pharma's tralokinumab after rejection 8 months ago

Eight months after Leo Pharma's atopic eczema treatment, tralokinumab, was rejected in the US, the FDA gives the Danish firm's drug the thumbs-up. Leo Pharma can now market and sell the drug in the US, which could double the company's size, says Leo Pharma executive Becki Morison.

Leo Pharma is turning a page with the FDA's historic approval of tralokinumab as a treatment of atopic eczema, says a Leo Pharma executive | Photo: Leo Pharma / PR

The US Food and Drug Administration (FDA) approves of Leo Pharma's biologic drug, tralokinumab, against atopic eczema in adults, Leo Pharma announce in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs